GUMM - Eliminate the Common Cold Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GUMM - Eliminate the Common Cold

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DanZ who wrote (4194)	1/7/2003 9:01:12 AM
From: Mike M	Read Replies (1) of 5582

Sorry to have to post this but you can't seem to find a Truthseeker when you need one. <g> Reuters: biz.yahoo.com Reuters Matrixx Initiatives boosts 2002 revenue view Tuesday January 7, 8:15 am ET PHOENIX, Jan 7 (Reuters) - Matrixx Initiatives (NasdaqNM:MTXX - News), a maker of nasally-delivered, over-the-counter cold medication, said on Tuesday that it expects to beat its prior revenue forecast for 2002, due to strong demand after the release of new research highlighted the effectiveness of an ingredient it uses in its products. Matrixx, whose products are marketed under the Zicam name, said its 2002 sales are expected to increase by more than 40 percent over 2001, driven by a doubling of fourth-quarter sales over the prior-year period. Research indicating that an ingredient used in some of its products -- zinc gluconate -- helped reduce cold symptoms, had increased interest in its products from retailers, Matrixx said. Matrixx also said it expects to post a small profit from operations in the fourth quarter. It also said it was on track to be profitable and cash flow positive for the full year.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next